TABLE 4.
Lipid | TLB | TCC-noMIAC | TCC-MIAC | P (TLB vs. TCC-noMIAC) | P (TLB vs. TCC-MIAC) | P (TCC-noMIAC vs. TCC-MIAC) |
9(10)-EpOME | 217.2 (172.2–384.9) [35] | 113.0 (76.2–166.1) [12] | 239.8 (157.4–370.2) [12] | 1.20 × 10−4 | 0.97 | 0.03 |
12(13)-EpOME | 150.2 (106.4–212.7) [35] | 59.9 (51.5–107.3) [12] | 116.7 (79.5–212.7) [12] | 1.06 × 10−4 | 0.28 | 0.16 |
8(9)-EpETrE | 45.7 (28.9–59.9) [35] | 14.4 (10.2–21.5) [12] | 33.2 (25.2–39.7) [12] | 4.97 × 10−7 | 0.21 | 0.02 |
11(12)-EpETrE | 200.2 (166.1–307.6) [35] | 67.4 (52.1–113.1) [12] | 177.8 (129.3–210.0) [12] | 6.77 × 10−6 | 0.24 | 0.01 |
14(15)-EpETrE | 109.6 (83.7–162.9) [35] | 45.1 (23.2–67.3) [12] | 80.7 (71.8–115.6) [12] | 2.86 × 10−6 | 0.10 | 0.02 |
8(9)-EpETE (ω-3) | 2.94 (1.83–3.86) [33] | 0.02 (0.02–0.02) [1] | 0.02 (0.02–0.02) [2] | 1.26 × 10−6 | 5.33 × 10−6 | NA |
11(12)-EpETE (ω-3) | 14.6 (11.1–19.4) [35] | 1.94 (1.42–2.96) [10] | 3.45 (2.79–6.00) [11] | 6.87 × 10−7 | 7.70 × 10−8 | 0.07 |
17(18)-EpETE (ω-3) | 5.94 (3.92–8.80) [35] | 0.02 (0.02–0.93) [5] | 1.62 (0.51–2.02) [9] | 5.81 × 10−7 | 7.55 × 10−6 | 0.04 |
16(17)-EpDPE (ω-3) | 9.62 (7.39–14.5) [35] | 3.00 (2.32–3.84) [11] | 5.21 (2.76–7.58) [12] | 6.01 × 10−6 | 3.55 × 10−3 | 0.05 |
19(20)-EpDPE (ω-3) | 13.4 (8.63–18.9) [35] | 3.02 (2.17–4.12) [12] | 6.46 (3.54–6.89) [12] | 1.06 × 10−6 | 1.55 × 10−4 | 0.02 |
EpDPE, epoxy docosapentaenoic acid; EpETE, epoxy eicosatetraenoic acid; EpETrE, epoxy eicosatrienoic acid; EpOME, epoxy octadecenoic acid. All concentrations are in nM. Values in parentheses are interquartile ranges of analyte concentrations in nM, and those in brackets are number of samples with detectable levels of the corresponding lipid mediators. All P values are derived from Wilcoxon tests. P values <0.05 were italicized.